Skip to Content

Notice

Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Applications Concerning Specific Inihibitors and Therapeutic Agents for Botulinum Toxin B and Tetanus Neurotoxins

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Department of the Army, DOD.

ACTION:

Notice.

SUMMARY:

In accordance with 37 CFR 404.6 and 404.7, announcement is made of the availability for licensing of the related U.S. patent applications concerning “Specific Inhibitors and therapeutic Agents for Botulinum Toxin B and Tetanus Neurotoxins” listed below. The United States Government, as represented by the Secretary of the Army, has rights in these inventions. Foreign rights are also available.

ADDRESSES:

Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 1702-5012.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619-6664, bh at telefax (301) 619-5034.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

The following patents are available for licensing:

(1) U.S. Patent Application No.: 09/570,022.

Filed: May 12, 2000.

Title: Previns as Specific Inhibitors and Therapeutic Agents for Botulinum

Toxin B and Tetanus Neurotoxins.

Supplementary Information: The compounds of the invention may be used as molecular building blocks to create compounds that are optimized for inhibiting the protease activity of Botulinum B and tetanus toxins. Foreign rights (PCT/US00/13215) are also available.

(2) U.S. Patent Application No.: 09/570,023.

Filed: May 12, 2000.Start Printed Page 50653

Title: Buforin I as a Specific Inhibitor and Therapeutic Agent for Botulinum Toxin B and Tetanus Neurotoxins.

Supplementary Information: The compounds of the invention may be used to inhibit the protease activity of Botulinum B and tetanus toxins. . Foreign rights (PCT/US00/12909) are also available.

(3) U.S. Patent Application No.: 09/979,101.

Filed: November 19, 2001.

Title: Previns as Specific Inhibitors and Therapeutic Agents for Botulinum Toxin B and Tetanus Neurotoxins.

Supplementary Information: The compounds of the invention may be used as molecular building blocks to create compounds that are optimized for inhibiting the protease activity of Botulinum B and tetanus toxins. Foreign rights (PCT/US00/13215) are also available.

Start Signature

Luz D. Ortiz,

Army Federal Register Liaison Officer.

End Signature End Supplemental Information

[FR Doc. 02-19712 Filed 8-2-02; 8:45 am]

BILLING CODE 3910-08-M